JP2007535520A - 抗腫瘍作用を有するインドール及びアザインドール誘導体 - Google Patents

抗腫瘍作用を有するインドール及びアザインドール誘導体 Download PDF

Info

Publication number
JP2007535520A
JP2007535520A JP2007510035A JP2007510035A JP2007535520A JP 2007535520 A JP2007535520 A JP 2007535520A JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007535520 A JP2007535520 A JP 2007535520A
Authority
JP
Japan
Prior art keywords
dimethoxy
indole
methoxyphenyl
group
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007510035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535520A5 (https=
Inventor
ファリナ・カルロ
ガガリアルディ・ステファニア
ミシアノ・パオラ
セレスティニ・パオロ
ズニノ・フランコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NiKem Research SRL
Original Assignee
NiKem Research SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NiKem Research SRL filed Critical NiKem Research SRL
Publication of JP2007535520A publication Critical patent/JP2007535520A/ja
Publication of JP2007535520A5 publication Critical patent/JP2007535520A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2007510035A 2004-04-30 2005-04-27 抗腫瘍作用を有するインドール及びアザインドール誘導体 Pending JP2007535520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000874A ITMI20040874A1 (it) 2004-04-30 2004-04-30 Derivati indolici ed azaindolici con azione antitumorale
PCT/EP2005/051908 WO2005105213A2 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Publications (2)

Publication Number Publication Date
JP2007535520A true JP2007535520A (ja) 2007-12-06
JP2007535520A5 JP2007535520A5 (https=) 2008-06-19

Family

ID=34968098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510035A Pending JP2007535520A (ja) 2004-04-30 2005-04-27 抗腫瘍作用を有するインドール及びアザインドール誘導体

Country Status (7)

Country Link
US (1) US20070248672A1 (https=)
EP (1) EP1750687A2 (https=)
JP (1) JP2007535520A (https=)
AU (1) AU2005237788A1 (https=)
CA (1) CA2564249A1 (https=)
IT (1) ITMI20040874A1 (https=)
WO (1) WO2005105213A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150058441A (ko) * 2012-09-21 2015-05-28 비보룩스 아베 고형 종양의 치료 수단 및 방법
JP2016516828A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2018521986A (ja) * 2015-06-17 2018-08-09 ファイザー・インク 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
EP1779849A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
EP2134176A4 (en) * 2007-03-30 2012-08-29 Brigham & Womens Hospital COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES
CA2951295C (en) 2007-04-16 2020-04-28 Abbvie Inc. 7-nonsubstituted indole mcl-1 inhibitors
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
IN2012DN02555A (https=) * 2009-10-07 2015-08-28 Karobio Ab
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CN104203951B (zh) 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
WO2013138568A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US11866409B2 (en) 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
AU2019325685B2 (en) 2018-08-24 2025-07-24 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1286701A (en) * 1969-02-12 1972-08-23 Sumitomo Chemical Co Pyridophenone derivatives and conversion to benzodiazepine derivatives
JPS4969698A (https=) * 1972-09-25 1974-07-05
JPS5566578A (en) * 1978-10-02 1980-05-20 Schering Corp Novel 22substitutedd33heterocyclic indoles* their manufacture and medical composition containing them
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
EP0643059A1 (en) * 1993-09-15 1995-03-15 Pfizer Limited 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2003039539A2 (de) * 2001-11-09 2003-05-15 Merck Patent Gmbh Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
US20030105140A1 (en) * 2000-12-07 2003-06-05 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105140A (en) * 1870-07-05 Improvement in cigar-wrapping machines
CA1012147A (en) * 1972-09-25 1977-06-14 Hoffmann-La Roche Limited Indolo quinoline derivatives
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1286701A (en) * 1969-02-12 1972-08-23 Sumitomo Chemical Co Pyridophenone derivatives and conversion to benzodiazepine derivatives
JPS4969698A (https=) * 1972-09-25 1974-07-05
JPS5566578A (en) * 1978-10-02 1980-05-20 Schering Corp Novel 22substitutedd33heterocyclic indoles* their manufacture and medical composition containing them
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
EP0643059A1 (en) * 1993-09-15 1995-03-15 Pfizer Limited 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
US20030105140A1 (en) * 2000-12-07 2003-06-05 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2003039539A2 (de) * 2001-11-09 2003-05-15 Merck Patent Gmbh Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150058441A (ko) * 2012-09-21 2015-05-28 비보룩스 아베 고형 종양의 치료 수단 및 방법
KR102190768B1 (ko) 2012-09-21 2020-12-14 비보룩스 아베 고형 종양의 치료 수단 및 방법
JP2016516828A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2018521986A (ja) * 2015-06-17 2018-08-09 ファイザー・インク 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
ITMI20040874A1 (it) 2004-07-30
US20070248672A1 (en) 2007-10-25
CA2564249A1 (en) 2005-11-10
AU2005237788A1 (en) 2005-11-10
WO2005105213A3 (en) 2006-06-22
EP1750687A2 (en) 2007-02-14
WO2005105213A2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
JP2007535520A (ja) 抗腫瘍作用を有するインドール及びアザインドール誘導体
US10851092B2 (en) Pyridine compound
JP6912486B2 (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
TWI567059B (zh) 吡咯啶－２，５－二酮衍生物、醫藥組合物及用做為ｉｄｏ１抑制劑之方法
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CN112867721A (zh) Sting激动性化合物
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN105683166A (zh) 取代的嘧啶Bmi-1抑制剂
JP2021107456A (ja) インドリノン化合物の使用
CA3107548A1 (en) Smad3 inhibitors
AU2010333083B2 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2655359B1 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2010096395A1 (en) Amides as kinase inhibitors
CN104662022A (zh) 治疗实体瘤的手段和方法
EP3397632A1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2016153394A1 (ru) Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
HK40052813A (en) Pyridine salts and process
HK40053745A (en) Sting-agonist compound
HK40045137B (zh) Smad3抑制剂
HK40053745B (zh) Sting激动性化合物
HK40005148B (en) Pyridine compound
HK40005148A (en) Pyridine compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124